key: cord-0709773-1cictijf
authors: Ricard, Nicolas; Bailly, Sabine; Guignabert, Christophe; Simons, Michael
title: The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy
date: 2021-02-24
journal: Nat Rev Cardiol
DOI: 10.1038/s41569-021-00517-4
sha: fff9f7976a67abc8dd73b8d488451c23387bdc92
doc_id: 709773
cord_uid: 1cictijf

Endothelial cells are at the interface between circulating blood and tissues. This position confers on them a crucial role in controlling oxygen and nutrient exchange and cellular trafficking between blood and the perfused organs. The endothelium adopts a structure that is specific to the needs and function of each tissue and organ and is subject to tissue-specific signalling input. In adults, endothelial cells are quiescent, meaning that they are not proliferating. Quiescence was considered to be a state in which endothelial cells are not stimulated but are instead slumbering and awaiting activating signals. However, new evidence shows that quiescent endothelium is fully awake, that it constantly receives and initiates functionally important signalling inputs and that this state is actively regulated. Signalling pathways involved in the maintenance of functionally quiescent endothelia are starting to be identified and are a combination of endocrine, autocrine, paracrine and mechanical inputs. The paracrine pathways confer a microenvironment on the endothelial cells that is specific to the perfused organs and tissues. In this Review, we present the current knowledge of organ-specific signalling pathways involved in the maintenance of endothelial quiescence and the pathologies associated with their disruption. Linking organ-specific pathways and human vascular pathologies will pave the way towards the development of innovative preventive strategies and the identification of new therapeutic targets.

The endothelium forms the innermost layer of blood ves sels and lymphatic vessels and is best viewed as a multi functional organ with both systemic and tissue specific roles. At the whole organism level, the endothelium reg ulates oxygen and nutrient supply, immune cell traffick ing and inflammation 1 , haemostasis and coagulation 2 , vasomotor tone 3 , blood vessel permeability 4 and angiogenesis 5 . In addition, the endothelium has a num ber of organ specific functions including regulation of organ size and function (myocardial hypertrophy 6 , liver size and function 7 , pulmonary alveolar repair 8 and kidney function 9, 10 ) .

Given this heterogeneity of endothelial cell function, it is not surprising that studies show a remarkable het erogeneity of gene expression profiles in endothelial cells from different organs 11 . Interestingly, these expression profiles are functionally matched to local tissue needs. Microenvironment stimuli (shear stress, hypoxia and the presence of specific growth factors, cytokines and hormones) and epigenetics define and continu ously optimize local characteristics of endothelial cells. Epigenetic signatures that regulate the basal expression of endothelial specific genes in different organs are specified during embryonic development and con served during mitotic cycles 12 . Transcriptome analysis of endothelial cells from different tissues revealed hetero geneous gene expression signatures even after several passages in cell culture, indicating that tissue specific epigenetic modifications participate in the regulation of organotypic transcriptomic profiles 13, 14 . However, after long term cell culture, which removes endothelial cells from their in vivo microenvironment, approximately 50% of gene expression patterns are lost 15 , and major architectural characteristics, such as fenestrae, also disappear 16 .

To characterize organotypic endothelial specificity as close to in vivo conditions as possible, many groups have utilized microarray or RNA sequencing (RNA seq) of endothelial cells isolated by flow cytometry without the cell culture step 11, 17 . Single cell RNA seq of endothe lial cells isolated from adult male mice identified tran scriptomic signatures of quiescent arterial, venous, capillary and lymphatic endothelial cells in 11 differ ent tissues 11 . Interestingly, lymphatic endothelial cells The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy Nicolas Ricard 1 , Sabine Bailly 2 , Christophe Guignabert 3, 4 and Michael Simons 1, 5 ✉ Abstract | Endothelial cells are at the interface between circulating blood and tissues. This position confers on them a crucial role in controlling oxygen and nutrient exchange and cellular trafficking between blood and the perfused organs. The endothelium adopts a structure that is specific to the needs and function of each tissue and organ and is subject to tissue-specific signalling input. In adults, endothelial cells are quiescent, meaning that they are not proliferating. Quiescence was considered to be a state in which endothelial cells are not stimulated but are instead slumbering and awaiting activating signals. However, new evidence shows that quiescent endothelium is fully awake, that it constantly receives and initiates functionally important signalling inputs and that this state is actively regulated. Signalling pathways involved in the maintenance of functionally quiescent endothelia are starting to be identified and are a combination of endocrine, autocrine, paracrine and mechanical inputs. The paracrine pathways confer a microenvironment on the endothelial cells that is specific to the perfused organs and tissues. In this Review, we present the current knowledge of organ-specific signalling pathways involved in the maintenance of endothelial quiescence and the pathologies associated with their disruption. Linking organ-specific pathways and human vascular pathologies will pave the way towards the development of innovative preventive strategies and the identification of new therapeutic targets. from all the tissues cluster together, suggesting that the molecular signature of lymphatic endothelial cells is not tissue specific. By contrast, arterial and venous endothe lial cells from a specific tissue clustered together, show ing that vascular endothelial cell heterogeneity comes mainly from tissue specificity rather than arterial, capil lary or venous identity. Moreover, capillary endothelial cells that are involved in gas, ion, metabolite and hor mone exchange between the blood and tissues have the highest heterogeneity among tissues 11 .

Structural differences in the capillary endothelium were first described in the 1960s with the use of elec tron microscopy 18 . Three major types of capillaries exist (continuous, fenestrated and discontinuous). The capillary type of an organ is related to its functions 19 . Most organs have barrier forming, continuous capillar ies (lungs, brain, skin and heart) with tightly connected endothelial cells surrounded by a continuous basement membrane. This architecture permits diffusion of water, small solutes and lipid soluble materials, while preclud ing the passage of cells or pathogens. By contrast, fenes trated capillaries have intracellular pores (windows) with a diaphragm and are found in renal glomeruli, exocrine glands, endocrine glands and intestinal mucosa. These fenestrae increase permeability to fluids and solutes, but not macromolecules 20 . Sinusoids are fenestrated capillar ies with gaps instead of pores between endothelial cells and a thinner basement membrane than in continuous or fenestrated endothelia and are present in the liver, spleen and bone marrow. The gaps found in sinusoids facilitate selective exchange of materials.

Structural differences notwithstanding, normal endothelial cells everywhere are quiescent. This quies cent state is defined by minimal or absent endothelial proliferation and migration, minimal or no vascular leakage across the endothelial barrier and minimal (or fully absent) expression of leukocyte adhesion mol ecules. Indeed, the half life of a normal endothelial cell is an estimated 6 years in the heart as measured by 14 C incorporation 21 , and proliferative activity is absent (except in the liver and spleen, where about 1% of endothelial cells proliferate in a quiescent state 11 ). However, this 'quiescent' endothelium performs lots of active work, from secretion of paracrine and endocrine factors to active support of barrier maintenance for cell survival. Remarkably, little attention has been paid to what controls this 'active quiescence' and what main tains vascular normalcy under physiological conditions (Fig. 1) . Although much effort has been expended on exploration of signalling pathways underlying endothe lial cell activation and proliferation, almost no attention has been given to the signalling events that main tain endothelial normalcy and quiescence. The latest advances in this area are the subject of this Review.

The fibroblast growth factor (FGF) signalling cascade includes a family of 18 ligands, four receptor tyrosine kinases (RTK) (FGFR1-FGFR4) and several accessory molecules such as Klotho proteins and syndecans 22 . After FGFs bind to their high affinity RTKs, several intracellular pathways are activated, including the phosphoinositide 3 kinase (PI3K)-AKT pathway and mitogen activated protein kinase (MAPK) pathways mediated by extracellular signal regulated kinase 1 (ERK1) and ERK2 (reF. 22 ).

The extensive structural overlap and cross reactivity among FGF ligands and receptors represent a real chal lenge to identifying the function of FGF signalling in the endothelium. Results from studies in mice with knock out of individual Fgf genes or individual Fgfr genes are hard to interpret because of functional redundancy, whereas attempts to use FGFR chemical inhibitors are hampered by the low specificity and cross reactivity of these compounds. Successful strategies to circum vent the redundancy in the FGF family and investigate FGF signalling include mice with knockout of multiple 23 )), the use of soluble FGFR traps that target vari ous FGF family members 24 , and endothelial cell specific expression of a dominant negative FGFR1 construct that can inactivate all four FGF receptors 25 . Mice with con ditional endothelial cell specific deletion of Fgfr1 and Fgfr2 are viable, with no vascular developmental defects and no alterations in vascular homeostasis 26 . However, postnatal endothelial cell specific knockout of Fgfr1 in mice with global knockout of Fgfr3 results in impaired development of blood and lymphatic vessels 23 . A soluble receptor trap strategy was tested with the use of a solu ble FGFR1 trap (sFGFR1) that binds to a large number of FGFs 24 . In this study, transient FGF inhibition was achieved in vivo in mice via adenovirus mediated sys temic expression of sFGFR1. This FGF inhibition led to an increase in vascular permeability and, eventually, pul monary and myocardial haemorrhages, demonstrating the necessity for FGF signalling in the maintenance of vascular integrity 24 (Table 1) . A particularly interesting finding was the disrupted endothelial cell-cell junctions in large vessels, such as the femoral artery, carotid artery and jugular vein (Table 1) . One possible explanation for the disrupted endothelial cell-cell junctions is that the loss of FGF signalling decreases the expression of the phosphatase SHP2 (also known as PTPN11), thereby increasing phosphorylation of the junctional protein VE cadherin on tyrosine 658, which, in turn, results in loss of the VE cadherin-β catenin interaction 27 . The intracellular kinase SRC can also phosphorylate VE cadherin, especially in venous endothelial cells 28 . Phosphorylated VE cadherin is internalized and ubiq uitinated in response to inflammatory mediators 28 . However, phosphorylation of VE cadherin in the absence of inflammatory mediators is not sufficient for induction of vascular permeability 28 .

• Quiescent endothelial cells require active maintenance to preserve normalcy in a tissue-specific manner. • Dysregulation of signalling pathways involved in endothelial normalcy maintenance leads to endothelial dysfunction and vascular pathologies. • Endothelial quiescence and normalcy are important for disease resilience.

• Identification of organ-specific signalling pathways that maintain endothelial normalcy and quiescence will lead to new therapeutic targets supporting disease resilience and treatment of associated vascular pathologies.

www.nature.com/nrcardio 0123456789();:

The FGF signalling cascade also maintains endothe lial cell identity. FGF2 stimulation decreases expression of the transforming growth factor β (TGFβ) receptors (TGFβRs), TGFβ ligands (especially TGFβ2) and the major intracellular TGFβ signal transducer SMAD2 (reFs 29, 30 ). FGF driven suppression of TGFβ signal ling reduces endothelial to mesenchymal transition (EndMT) 31, 32 (Table 1) , a state in which endothelial cells lose the expression of important endothelial genes and acquire mesenchymal cell like characteristics, including increased migration and proliferation 32 . Mechanistically, FGF signalling controls the cellular levels of the let7 microRNA family 30 , which targets a number of TGFβ family members. A reduction in let7 expression results in substantial increases in the level and activity of TGFβ ligands and TGFβRs in vitro and in vivo 30 . Also, addi tion of FGF2 to human umbilical vein endothelial cells in vitro increases the expression of miR20a, which targets the TGFβRs 33 , another mechanism involved in FGF-TGFβ crosstalk. In addition, FGF signalling is cru cial for the expression of the endothelial receptor vas cular endothelial growth factor receptor 2 (VEGFR2), the primary signalling receptor of vascular endothelial growth factor A (VEGFA) 25 .

Endothelial cells are located at the interface with the circulating blood and, therefore, are subject to shear stress resulting from the flow of blood in the vasculature. Shear stress can be linear, pulsatile or disturbed depend ing on location (for example, near arterial bifurcations and along the aortic arch inner curvature) and vary in strength. Endothelial cell sensing of shear stress is a com plex process that is reviewed elsewhere 34 . The proteogly can syndecan 4 is one element of the shear stress sensing complex. Indeed, loss of endothelial syndecan 4 in mice results in impaired alignment of endothelial cells under flow 35 . Given that syndecan 4 is an important modula tor of FGF2 signalling [36] [37] [38] , this study suggests that flow modulates FGF signalling. Furthermore, shear stress can directly affect the expression of endothelial FGF recep tors. In particular, decreased FGFR1 expression has been observed in endothelial cells in areas of disturbed shear stress 39 . In vitro studies have confirmed the relationship between the level of endothelial FGFR1 expression and the magnitude and type of shear stress 39 .

Loss of FGF signalling in endothelial cells in areas of high shear stress has been linked to increased athero sclerotic plaque growth 39 (Table 2 ). Atherosclerosis is a progressive disease characterized by gradual intracel lular lipid deposition in the vasculature leading to the formation of atherosclerotic plaques 40, 41 . At these sites, endothelial cells acquire a pro inflammatory pheno type, which predisposes to atherosclerotic plaque development 41 Paracrine stimulation confers a tissue-specific microenvironment to the endothelium. For example, vascular endothelial growth factor (VEGF) signalling is crucial to the formation and maintenance of fenestrated endothelia, whereas paracrine WNT signalling induces formation and maintenance of continuous endothelial lining, which is crucial for vascular integrity in general and that of the bloodbrain barrier in particular. Autocrine transforming growth factorβ (TGFβ) signalling is a signature of endothelial cell dysfunction. ANG1, angiopoietin 1; ACVR2A, activin A receptor type 2A; ALK, activin receptor-like kinase; BMP9, bone morphogenetic protein 9; BMPR2, bone morphogenetic protein receptor type 2; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; LRP, lipoprotein receptor-related protein; TGFβR, transforming growth factorβ receptor; TIE2, angiopoietin 1 receptor; VEGFR, vascular endothelial growth factor receptor.

EndMT 39 . TGFβ signalling further promotes an inflam matory phenotype in endothelial cells, thereby estab lishing a feed forward loop between inflammation and TGFβ pathway activation 39, 42 . In patients with coronary artery disease, a strong correlation exists between dis ease progression and loss of FGFR1 expression and activation of TGFβ signalling in endothelial cells of the left main coronary artery, with up to 70% of endothe lial cells overlying atherosclerotic plaques expressing mesenchymal markers 39 (Table 2 ). Syndecan 4, a proteo glycan that increases FGF2 signalling, protects against atherosclerotic plaque formation in mice 35 , highlighting the protective role of endothelial FGF signalling against atherosclerosis.

VEGF signalling VEGF is the most studied angiogenic growth factor. All members of the VEGF family have important functions in the endothelium. VEGFA and VEGFC are key drivers of angiogenesis and lymphangiogenesis, respectively 43 . VEGFB is involved in the regulation of endothelial cell metabolism 44 , whereas the function of VEGFD is less clear 45 . A closely related growth factor, placental growth factor, is crucial for placental angiogenesis 46 . All the Bmpr2 endothelial knockout Not inducible Spontaneous pulmonary hypertension in 40% of adult animals 168 All studies were in mice except where indicated. ALK1, activin receptor-like kinase 1; BMP, bone morphogenetic protein; ERK, extracellular signal-regulated kinase; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; PV1, plasmalemma vesicle protein 1; SHH, sonic hedgehog; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.

www.nature.com/nrcardio VEGF ligands function via three related high affinity tyrosine kinase receptors (VEGFR1-VEGFR3) and a host of auxiliary signalling molecules including neuro pilins and syndecans 43 . VEGFR2 is the principal sig nalling VEGFR in blood endothelial cells, whereas both VEGFR2 and VEGFR3 are involved in lymphatic endothelial cell VEGF signalling 45 . Similar to FGF ligand binding to FGFRs, VEGF ligand binding to VEGFR2 activates several intracellular pathways, including PI3K-AKT and MAPK (including ERK1, ERK2 and p38 MAPK) pathways, among a number of others 43 . Of these VEGF induced pathways, VEGF mediated activation of ERK1 and ERK2 is thought to be crucial during embry onic vascular development and in angiogenic settings in adult tissues 43, 47 .

The role of VEGF-VEGFR2 signalling in angiogen esis is well established. However, the role of this sig nalling cascade in the quiescent endothelium remains unclear. Interestingly, VEGF ligands are expressed by a number of specialized cell types, such as podocytes, choroid plexus epithelium and hepatocytes in adult mice 48 . Studies using mice expressing the VEGF-lacZ reporter construct showed that VEGFA is expressed in cells overlying fenestrated and sinusoidal blood vessels, such as podocytes in the kidney and hepatocytes in the liver, as well as in tissues with secretory functions 48 . Furthermore, VEGFR2 in the adjacent endothelial cells was phosphorylated, demonstrating paracrine activ ity of the non endothelial VEGF in these specialized environments.

Local effects. The importance of paracrine VEGFA signalling in quiescent endothelium is well docu mented in glomerulus endothelium 49 ( Fig. 1 ; Table 1 ). Renal glomeruli are composed of fenestrated capillary endothelial cells and highly specialized epithelial cells (podocytes) separated by a glomerular basement mem brane. Glomerular podocytes continuously express high levels of VEGFA. Constitutive heterozygous deletion of Vegfa in podocytes in mice leads to endotheliosis (swell ing of endothelial cells with a partial loss of fenestra tions) by 2.5 weeks of age 49 . By 6.5 weeks of age, mice Nature reviews | Cardiology with heterozygous deletion of Vegfa have an expanded glomerular basement membrane and a near complete loss of endothelial fenestration. The outcome is termi nal renal failure with nephrotic syndrome at 9 weeks of age (Table 1) . Interestingly, constitutive overexpression of Vegfa in podocytes in mice leads to a different kid ney disease 49 . In this case, by 5 days of age, mice have a collapsing glomerulopathy characterized by kidney haemorrhages, proteinuria and complete collapse of the capillary loops, with no or few multinucleated endothelial cells (Table 1 ). Induction of Vegfa overex pression in podocytes of adult mice induces a different phenotype from that of mice with non inducible Vegfa overexpression 49, 50 . Inducible Vegfa overexpression in podocytes in adult mice also leads to kidney failure, pro teinuria, glomerular basement membrane thickening, slit diaphragm loss and podocyte effacement, although endothelial cells are mostly unaffected (no endotheliosis or loss of fenestration) 50 (Table 1 ). Together, these data show the crucial requirement for finely balanced VEGF signalling in the filtration barrier of the glomeruli at different developmental stages. Similar to the kidney, ablation of VEGF in endocrine glands leads to the loss of endothelial fenestrations 51 . Deletion of Vegfa 52 or overexpression of a soluble form of Vegfr1 (reF. 53 ) in pancreatic β cells in mice results in a loss of endothelial fenestrations in pancreatic islets (Table 1) . A similar loss of endothelial fenestrations is observed in thyroid capillaries following pan endothelial Vegfr2 deletion in mice 54 (Table 1 ).

In addition to paracrine activation of VEGF signal ling, an autocrine VEGF loop is also crucial to the integ rity of the quiescent endothelium 55 (Table 1) . VEGFA expression in pulmonary, aortic and intestinal blood ves sels in adult mice is patchy 55 . Constitutive homozygous deletion of Vegfa in endothelial cells results in lethal ity at any age, including around 25% lethality in adult mice, with a peak in death at 20-25 weeks after birth, as a result of multiorgan haemorrhage (in the spleen, kidney, brain, intestines, heart and lungs), intestinal perforations and myocardial infarction 55 . These haemorrhages and thrombotic events are the consequence of endothe lial cell apoptosis 55 . Interestingly, endothelial specific knockout of Vegfa in mice does not induce a loss of endothelial fenestrations in renal glomeruli 55 , unlike in mice with loss of paracrine VEGFA signalling. These differences in phenotype imply differences in VEGF signalling circuits when activated in an autocrine ver sus paracrine manner. However, the identity of these circuits remains unknown. Finally, small amounts of circulating VEGF ligands are found in blood. Whether the presence of VEGFs in blood implies the existence of endocrine signalling and what that might entail has not been established.

The VEGF pathway is also activated by shear stress. VEGFR2 is part of a complex with VE cadherin and platelet endothelial cell adhesion molecule 56 , which allows endothelial cells to sense shear stress. Increased shear stress leads to ligand independent activation of VEGFR2 by SRC, activation of AKT and then activation of endothelial nitric oxide synthase (eNOS; also known as NOS3) to induce vasodilatation 57 .

Systemic hypertension. In addition to specific effects in various organs, VEGFs have a number of systemic effects that became evident with the widespread clinical use of VEGF neutralizing agents and tyrosine kinase inhibi tors that target VEGFR2. Use of anti VEGF therapies can often trigger the development of systemic hyper tension owing to decreased synthesis of the vasodila tor nitric oxide (NO) and increased expression of the vasoconstrictor endothelin 1 (ET1) [58] [59] [60] [61] [62] (Table 2 ). The decrease in blood NO levels is due to a reduction in the expression of eNOS, which catalyses the synthesis of NO from l arginine. However, specifically how decreased VEGF signalling leads to increased ET1 expression and whether a specific vascular bed is predominantly respon sible for NO or ET1 synthesis is unclear. Other adverse effects of anti VEGF therapies include protei nuria and membranous glomerulonephropathy, which can poten tially advance to renal failure 63 and are attributable to the requirement for VEGF in the maintenance of the renal vasculature and filtration units (Table 2 ). Finally, haemorrhages have been described in patients with can cer who were treated with sunitinib or sorafenib, two tyrosine kinase inhibitors targeting VEGFR2 signalling 64 ( Table 2 ).

Lack of VEGF signalling is responsible for the hyper tension in women with pre eclampsia, a common mater nal complication of pregnancy associated with oedema, renal failure and systemic hypertension (Table 2) . Syncytiotrophoblasts, a placental cell type, secrete a sol uble form of VEGFR1 (sVEGFR1) and if this secretion is abnormally elevated, increased amounts of circulat ing sVEGFR1 sequestrate VEGFA, initiating the disease process [65] [66] [67] . Adenovirus mediated overexpression of sVEGFR1 in pregnant rats induced systemic hyperten sion, proteinuria and glomerular endotheliosis, similar to what is observed in patients with pre eclampsia 65 , and validating the requirement for sVEGFR1 in the patho genesis of pre eclampsia. Similar to the hypertension induced by the use of VEGF inhibitors, systemic hyper tension in patients with pre eclampsia is also driven by decreased NO production and increased ET1 levels in plasma 68, 69 . Interestingly, elevated plasma TGFβ2 levels in patients with systemic hypertension 70 and the changes in renal histology in patients with pre eclampsia 71 are similar to findings in mice with a systemic deletion of Erk1 and an inducible, endothelial specific deletion of Erk2 (Erk1 −/− Erk2 iEC−/− ) 10 (Table 1) .

Both FGF and VEGF signalling cascades activate endothelial ERK1 and ERK2 signalling 43 . A study from 2019 elucidated the function of ERK1 and ERK2 in the quiescent endothelium 10 . Inducible, endothelial specific deletion of Erk2 in adult Erk1 null mice led to universal lethality within 4 weeks 10 . Interestingly, the phenotypes of these mice are a combination of the phenotypes found after inhibition of the FGF pathway and the VEGF path way (Table 1 ). Erk1 −/− Erk2 iEC−/− mice have increased TGFβ signalling as a result of a decrease in let7 microRNA expression, leading to EndMT. This TGFβ induced EndMT has previously been observed after endothelial FGF pathway inhibition 30 . These Erk1 −/− Erk2 iEC−/− mice also develop systemic hypertension due to a loss of eNOS expression and increased ET1 expression, lose www.nature.com/nrcardio fenestrations in endocrine gland and kidney endothe lium, and develop kidney failure with proteinuria and endotheliosis of the glomerulus endothelium 10 . These phenotypes are very similar to those found in mice with VEGF pathway inhibition. Taken together, these results demonstrate the crucial function of the ERK1-ERK2 pathway in the maintenance of quies cent vasculature integrity and highlight the differences between VEGF mediated and FGF mediated activation of ERK1-ERK2.

Pulmonary vasculature. The function of VEGF in the pulmonary vasculature is less well defined. Pulmonary capillaries are continuous, which means they do not have fenestrations. Nevertheless, VEGF is important for the maintenance of the pulmonary vasculature. Inhibition of VEGF signalling in rats by treatment with the VEGFR blocker SU5416 leads to pruning of the pulmonary arterial vasculature, which, in turn, induces alveolar cell apoptosis and emphysema at high doses 72 (Table 1) . Interestingly, Notch signalling can attenuate the angio genic sprouting effect of VEGF signalling 73, 74 . Consistent with this notion, mice with a heterozygous deletion of Dll4 (which encodes the Delta like protein 4, a ligand of the Notch pathway), which is highly expressed in arte rial endothelial cells and is a target gene of VEGF signal ling, have pulmonary haemorrhages, suggesting a crucial role of VEGF signalling and the downstream Notch pathway in pulmonary endothelial cells 75 (Table 1) . Furthermore, some patients treated with neutralizing antibodies against DLL4 (demcizumab or enoticumab) or a bispecific antibody against DLL4 and VEGF (nav icixizumab) develop pulmonary hypertension [76] [77] [78] [79] ( Table 2 ). The cancer therapy drug dasatinib inhibits ephrin receptor signalling, which is directly connected to the VEGF signalling pathway by modulating VEGFR2 endocytosis 80 and activation of downstream pathways 81 . The interaction of these signalling pathways and the fact that multiple intracellular and cell surface kinases are simultaneously inhibited by dasatinib might explain why this therapy is associated with the development of pulmonary hypertension in some patients 82, 83 and aggravates pulmonary hypertension in rats 84 (Table 2) .

VEGF signalling also has an important role in vascu lar protection in patients with acute respiratory distress syndrome (ARDS) 85, 86 (Table 2 ). ARDS is characterized by diffuse alveolar damage leading to impaired gas exchange and is common in several pulmonary diseases, including viral pneumonitis (such as those caused by H1N1 influenza virus infection), severe acute respiratory syndrome and coronavirus disease 2019 (COVID19), in which ARDS is associated with intense bronchial and lung parenchyma inflammation 87, 88 . The early, exuda tive phase of ARDS is characterized by diffuse alveolar damage, disruption and loss of epithelial and endothelial cell-cell junctions, and alveolar oedema 89 . The exudative phase is followed by a proliferative phase that involves the formation of hyaline membranes on the epithelial side of the basement membrane and extensive cellular infiltrates in the alveolar spaces 90 . VEGFs are present in the normal alveolar space and probably serve to main tain alveolar function 85 . The loss of this protection, such as occurs with increased levels of VEGFA trap sVEGFR1 in the lungs, is predictive of the development of ARDS and of an increased risk of adverse outcomes among patients with ARDS 86 . At the same time, these protec tive effects of VEGF signalling are counterbalanced by the capacity of the same VEGFA to induce oedema and promote inflammation 85, [90] [91] [92] . Indeed, studies of patients with ARDS associated with viral vasculitis, such as those caused by hantavirus infection, have demonstrated a strong association between VEGF levels in the lungs and pulmonary oedema [93] [94] [95] .

This association renders VEGF an unappealing agent for ARDS therapy and emphasizes the need for a drug that selectively activates VEGF protective pathways while inhibiting its pro inflammatory signalling. However, the absence of a drug that differentiates between the ben eficial (cell survival) and detrimental (oedema) effects of VEGF signalling prevents the development of a promising new therapeutic modality.

Whereas the VEGF-ERK signalling axis is central to the maintenance of endothelial fenestrae of the kidney and endocrine glands, WNT signalling has an equally important role in the maintenance of tight junctions and the continuous endothelium of the central nervous system 96 . The WNT family is composed of ten WNT receptors (Frizzled 1-10), four WNT co receptors (LDL receptor related protein 5 (LRP5), LRP6, RTK like orphan receptor 2 and receptor like tyrosine kinase), and 16 WNT ligands (WNT1-WNT16). Canonical WNT signalling involves the binding of WNT ligands to Frizzled receptors and the co receptors LRP5 and LRP6. Phosphorylation of LRP5 and LRP6 recruits the β catenin destruction complex (Axin, casein kinase 1, glycogen synthase kinase 3 and adenomatous polyposis coli protein) from the cytoplasm to the plasma mem brane, where the complex cannot degrade β catenin. This stabilized form of β catenin accumulates and translocates to the nucleus to activate the transcription of WNT target genes. Glia and neurons produce WNT7a and WNT7b ligands (Fig. 1) , and binding of these WNT ligands to the receptor Frizzled 4 activates canonical WNT signalling in endothelial cells of the central ner vous system [97] [98] [99] . Upregulation of β catenin in endothe lial cells leads to increased expression of genes encoding tight junction components (claudin 1, claudin 3 and claudin 5) and the glucose transporter 1 (GLUT1) 97 . Simultaneously, expression of Plvap, the gene encoding plasmalemma vesicle protein 1 (PV1), which is the prin cipal component of endothelial fenestrae, is repressed in endothelial cells 97, 100 (Fig. 2) . This combined effect of WNT signalling is crucial to the integrity of the bloodbrain barrier (BBB). Indeed, endothelial cell specific deletion of Ctnnb1, the gene encoding β catenin, in adult mice leads to severe seizures, brain haemorrhages and death 96 (Table 1 ). Endothelial deletion of Fzd4, which encodes the receptor Frizzled 4, in adult mice leads to increased PV1 levels and decreased claudin 5 levels in retinal, cerebellar, spinal cord and olfactory bulb endothelial cells 98 (Fig. 2; Table 1 ). Therefore, the WNT pathway is a perfect example of how the cellular Nature reviews | Cardiology microenvironment can induce the final differentiation step of endothelial cells, leading to a highly specialized organotypic endothelium.

Similar to the paracrine WNT signalling path way, a paracrine sonic hedgehog (SHH) signalling pathway is also activated in the BBB 101 . Astrocytes in the BBB express the ligand SHH, which binds to and inactivates the receptor protein patched homologue 1 (PTCH1), which is expressed in brain endothelial cells 101 (Table 1) . Inactivation of PTCH1, in turn, results in the inactivation of the G protein coupled recep tor Smoothened (SMO), which leads to the activation of the gliomaassociated oncogene (GLI1). Genetic endothelialspecific deletion of Smo specifically led to an increase in BBB permeability in adult mice, mani fested by plasma protein leakage and decreased expres sion of junctional proteins (occludin, claudin 3, claudin 5 and tight junction protein ZO1) 101 . This increased BBB permeability induces a pro inflammatory pheno type in BBB endothelial cells with upregulation of intercellular adhesion molecule 1 (ICAM1) and recruit ment of circulating inflammatory cells 101 . Furthermore, SHH signalling also induces the expression of netrin 1 in the BBB endothelial cells, a laminin related protein that is critical for cell-cell junction and cell-substrate adhesion 102 .

Dysregulation of the WNT-β catenin pathway has been implicated in various central nervous system dis orders that involve BBB breakdown, including multi ple sclerosis 103 , Alzheimer disease 104 and Huntington disease 105 . The blood-retina barrier shares high similar ity with the BBB. Mutations in NDP, a gene encoding the WNT ligand Norrin and expressed in the blood-retina barrier, are linked to Norrie disease, a condition in which the blood-retina barrier integrity is compromised, lead ing to blindness 106,107 ( Table 2 ). Dysregulation of the SHH pathway is found in HIV associated neurocognitive disorders with disruption of BBB integrity 108 .

Angiopoietin signalling Angiopoietins (ANGs) are a family of secreted fac tors comprising ANG1, ANG2 and ANG3 (ANG4 in humans). Unlike the FGF and VEGF signalling path ways, which are involved in both pro angiogenic pro cesses and maintenance of endothelial cell quiescence signalling, ANG1 signalling is purely a quiescence sig nalling pathway in endothelial cells. ANG1 is expressed in mural cells and binds to the angiopoietin 1 receptor (Fig. 2 ; Table 1 ). The loss of TIE2 signalling reactivates the endothelium by weak ening endothelial cell-cell junctions 114, 115 , inducing the expression of pro inflammatory adhesion molecules, including ICAM1 and vascular cell adhesion molecule 1 (VCAM1) 112 , and increasing the levels of procoagulant proteins on the luminal surface of endothelial cells 116, 117 ( Table 1) . Intriguingly, ANG2-TIE2 interactions are context dependent -ANG2 acts as a TIE2 agonist under pathogen free conditions but as an antagonist under inflammatory conditions (such as infection and tumour necrosis factor (TNF) or lipopolysaccharide stimulation) 118 . TIE1 is an orphan receptor unable to bind any angiopoietin or other known ligands. TIE1 and TIE2 interact in the absence of a ligand 119 . Endothelial TIE1 is required for the agonist effects of paracrine ANG1 and autocrine ANG2 on TIE2 activation. During inflammation, the ectodomain of TIE1 in endothelial cells is cleaved, resulting in the loss of ANG2 agonist activity, thereby promoting vascular remodelling and leakiness 120 . TIE1 cleavage reduces, but does not abolish, ANG1 agonist activity. Despite AKT signalling functioning in different aspects of cellular regulation in multiple cell types, in the quiescent endothelium, AKT is considered to function as a survival pathway 121 . In vitro transduc tion of endothelial cells with a dominant negative Akt variant decreases endothelial viability by opposing the pro survival effects of VEGF 122 . However, a 2016 study in mice showed that the main function of the endothelial AKT pathway is not endothelial cell survival but mainte nance of adequate interactions between endothelial cells, pericytes and vascular smooth muscle cells 123 (Table 1) . Indeed, endothelial cell specific deletion of Akt1 in mice with global Akt2 deletion alters Jagged 1-Notch signalling between endothelial and mural cells, leading to apoptosis of vascular smooth muscle cells and peri cytes and subsequent vessel regression, particularly in coronary arteries 123 . However, endothelial cell apoptosis was not detected in these Akt2 −/− mice with endothelial cell specific Akt1 deletion. The regulation of Notch sig nalling by AKT following ANG1 stimulation in endothe lial cells is mediated by the endothelial transcriptional regulator ERG 124 . Inducible, endothelial cell specific deletion of Erg in mice leads to a phenotype similar to that produced by the deletion of Akt1 and Akt2, with a loss of vascular smooth muscle cell coverage and vascular regression 125 .

Clinical data have added a layer of complexity to our understanding of ANG-TIE signalling. Multiple cutaneous and mucosal venous malformations have been reported in patients carrying gain of function genetic variants in TEK (encoding TIE2) 126, 127 . This vascular malformation is characterized by the develop ment of soft, blue, compressive and localized lesions 128 . Histological features of these venous lesions include uneven endothelial cell lining, disorganized extracellu lar matrix structure, enlarged lumen and sparse mural cell coverage 128 . These lesions can be present at birth or present around puberty 128 . These gain of function TEK genetic variants result in autophosphorylation of TIE2 and excessive activation of the downstream AKT pathway in endothelial cells 129 . At the same time, secre tion by endothelial cells of platelet derived growth fac tor B, which is responsible for mural cell recruitment, is downregulated 129 . These observations suggest that, although TIE2 signalling is important for the switch from an activated to a quiescent endothelium, overacti vation of this pathway is deleterious. The mechanism responsible for ensuring the proper extent of TIE2 activation is currently unclear. Vascular endothelial protein tyrosine phosphatase (VEPTP), a vascular phos phatase, seems to be crucial in limiting TIE2 activation, because neutralization of VEPTP in vivo in mice results in vascular lesions similar to those seen in mice with gain of function TEK genetic variants 130, 131 .

The TGFβ superfamily includes a large pool of ligands, such as TGFβ1-TGFβ3, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), activins and inhibins and nodal. These ligands bind to a com plex of two dimers of a combination of type I receptors named activin receptor like kinase 1 (ALK1)-ALK7 and two dimers of type II receptors (BMP receptor type 2 (BMPR2), TGFβR, activin receptor type 2A and activin receptor type 2B), leading to the activation of a number of different canonical (SMAD dependent) and non canonical signalling cascades 132 . The major distinc tion between canonical BMP and TGF pathways is the phosphorylation of SMAD2-SMAD3 by TGFβ, activins, inhibins and nodal, whereas BMPs and certain GDFs phosphorylate SMAD1, SMAD5 and SMAD8.

BMP9 and BMP10 are circulating BMPs produced by the liver and the heart, respectively 133 . Both ligands bind the high affinity receptor ALK1, which is specif ically expressed by endothelial cells 134 . ALK1 signal ling is crucial for developmental angiogenesis [135] [136] [137] [138] . In addition, ALK1 also has a crucial role in the quiescent endothelium. Endothelial deletion of Alk1 in adult mice (aged 2 months) is lethal within 9-21 days of deletion, although the exact cause of death is still unknown 139 (Table 1) . Major autopsy findings included cardiac enlargement and haemorrhages in the lungs and the gastrointestinal tract 139 . Deletion of Alk1 in endothelial cells in adult mice also led to the spontaneous forma tion of arteriovenous malformations (AVMs) -direct shunts between arteries and veins -in the gastroin testinal tract and uterus 139 . AVMs were also suspected to be present in the lungs, but were difficult to assess because of the multiple haemorrhages in the lungs 139 . Furthermore, wounding can also induce de novo AVM formation in the skin of adult mice with Alk1 deletion 139 . Endoglin, the co receptor for ALK1, is also important for vascular quiescence. Endothelial specific deletion of Eng (which encodes endoglin) in adult mice resulted in wound induced AVMs in the skin, but no visceral AVMs were found 140 . However, spontaneous pelvic AVMs were shown in another study of mice with endothelial specific Eng deletion 141 (Table 1) . Interestingly, the pelvic area where the AVMs form after Eng deletion has high VEGFA levels 141 . Anti VEGF treatment blocked the for mation and maturation of AVMs in Alk1 knockout mice and Eng knockout mice 141, 142 . Together, these data sup port the concept that ALK1 and endoglin are required for the maintenance of endothelial quiescence in adult life to counteract an over exuberant endothelial proliferative response to VEGF signalling.

The molecular mechanism by which ALK1-endoglin signalling maintains the integrity of the quiescent endothelium is still unknown. BMP9 and BMP10 induce endothelial quiescence by inhibiting endothelial cell migration and proliferation in microvascular endothelial cells 134, 143 . Moreover, the BMP9-ALK1 signalling pathway inhibits the pro angiogenic VEGF-AKT1 pathway 144 . BMP9, which is produced by hepatic stellate cells, induces the fenestration of the sinusoidal endothelial cells 145 (Figs 1,2) . Deletion of Bmp9 in 129/Ola mice triggers hepatic fibrosis following sinusoidal capillarization (transformation of the fenestrated hepatic sinusoids into continuous capillaries, with synthesis of a basement membrane of collagen between the endothelial cells and the hepatocytes) 146 (Table 1) .

The BMP9-ALK1 pathway is also modulated by shear stress. Endoglin increases BMP9 signal ling through ALK1 in endothelial cells during shear stress 147 . This increased BMP9 activity is accomplished by an increase in the association between endoglin and ALK1 before their binding to the ligand 147 . Loss of eng in zebrafish leads to defective blood flow induced cell shape changes, resulting in enlarged vessels 148 . The primary cilia, which can function as a sensor of blood flow induced mechanical forces on endothelial cells, can also regulate BMP signalling. In vitro, the loss of BMP9 signalling through the cilium was shown to increase endothelial cell migration 149 . Together, these studies show that shear stress increases BMP9 signalling in quiescent endothelial cells.

Interestingly, stimulation of human pulmonary endothelial cells with BMP9 in vitro inhibits the TGFβ pathway by inducing the expression of inhibitory SMADs (SMAD6 and SMAD7) and by decreasing TGFβR2 expression 150 . These results identify a second pathway that inhibits TGFβ signalling in endothelial cells 10, 30 (Fig. 2) . Further evidence supporting the impor tance of TGFβ pathway inhibition in quiescent endothe lium is the increased expression of SMAD6 and SMAD7 observed in pulmonary endothelial cells of adult mice compared with pulmonary endothelial cells from infant mice, which are proliferative cells 151 . These studies firmly support the notion that BMP9-ALK1 signalling inhib its the TGFβ pathway in quiescent pulmonary endothe lial cells. The endothelial specific transcription factor ERG can also activate the BMP pathway by upregulat ing SMAD1 as well as inhibiting the TGFβ pathway by downregulating SMAD3 expression in the quiescent endothelium of the hepatic vasculature 152 .

Disruption of normal BMP signalling in quiescent endothelial cells is the molecular basis for hereditary haemorrhagic telangiectasia (HHT), a rare genetic vas cular disease (Table 2 ). HHT is characterized by recur rent nosebleeds, mucous telangiectasia and formation of AVMs 153, 154 . In most patients, HHT is caused by loss of function genetic variants in ENG or ACVRL1 (encoding ALK1) 155, 156 , and these variants decrease BMP9 signalling 157, 158 . Interestingly, a second variant on the somatically non mutated allele of ACVRL1 or ENG can be found in some lesions in patients with HHT 159 . These results establish HHT as a disease of decreased BMP9 and BMP10 signalling. AVMs in patients with HHT are predominantly found in the liver and lungs and, to a lesser extent, in the brain 160 . Interestingly, AVMs in the liver are more frequent in patients with HHT type 2 (patients carrying an ACVRL1 variant) than in patients with HHT type 1 (carrying an ENG variant), whereas the opposite is true for AVMs in the lung 160 . Whether AVMs are congenital or acquired during adult life is unclear. Given that most AVMs are asymptomatic, sparse data exist on AVM frequency in children and younger adults. One study found that, in patients with HHT type 2, hepatic AVMs were present in 67% of patients aged <45 years and in 93% of patients aged >45 years 161 . A similar difference was found in patients with HHT type 1 (hepatic AVMs were present in 46% of patients aged <45 years and in 78% of patients aged >45 years) 161 . With regard to pulmonary AVMs, a Canadian study compared the frequency of pulmonary AVMs in children (aged <18 years) and their parents 162 . In patients with HHT type 1, the frequency of pulmonary AVMs was similar in both groups, whereas among patients with HHT type 2, 8.3% of children had pulmonary AVMs compared with 25.9% of the parents 162 . Moreover, the incidence of HHT symptoms increases with age, and symptomatic AVMs in the liver are found in adult patients (aged >30 years) 163, 164 . Taken together, these data suggest that at least some AVMs can develop in adulthood because of alterations in endothelial quiescence and that AVM size increases with age leading to symptomatic AVMs in older patients. The hypothesis of an increase in VEGFA signalling as a result of the loss of BMP signalling owing to ACVRL1 or ENG variants was validated by data from a clinical trial showing that inhibition of VEGF in patients with HHT decreases the symptoms of HHT 165 .

The BMP pathway is also involved in the develop ment and progression of pulmonary arterial hyperten sion (PAH) ( Table 2 ). Heterozygous germline variants in BMPR2 underlie the main genetic susceptibility for PAH, found in 53-86% of patients with a family his tory of PAH and 14-35% of patients with idiopathic PAH 166 . Although the presence of a BMPR2 variation is neither necessary nor sufficient to cause PAH, a reduction in BMPR2 activity is currently viewed as the major molecular defect conferring a predisposition to develop PAH as well as an increased risk of progres sion of the disease 166, 167 . Constitutive deletion of Bmpr2 in endothelial cells in mice predisposed the animals to develop spontaneous PAH 168 , supporting the notion that disrupting BMP signalling in the endothelium is a risk factor for PAH. However, given the potential www.nature.com/nrcardio inhibitory role of BMPR2 in BMP signalling 169 , the exact effect of BMPR2 variants on BMP signalling in the pulmonary endothelium is unclear. The discov ery in some patients with PAH of variants in GDF2 (encoding BMP9), leading to decreased circulating BMP9 level, and variants in BMP10 revealed another layer of complexity of the regulation of the pulmonary endothelium and PAH pathogenesis [170] [171] [172] [173] . Therapy with BMP9 has been proposed as a strategy to compen sate for the loss of one BMPR2 allele in patients with PAH 150 . However, Bmp9 null mice do not develop spon taneous pulmonary hypertension, and these mice were even protected in experimental models of pulmonary hypertension 174 . Given these contradictory findings, further research is needed to clarify the role of BMP sig nalling in PAH. In particular, understanding how the reduction in the BMPR2 activity predisposes to PAH and how the BMP9-BMP10-BMPR2 axis contributes to the pathophysiology of PAH is essential. An early event that seems to be facilitated by dysfunction in the BMP9-BMP10-BMPR2 axis is the pro inflammatory phenotype of endothelial cells in PAH 175 . In PAH, dur ing the process of vascular remodelling, quiescent pul monary endothelial cells become activated and express high levels of adhesion molecules, such as VCAM1 and ICAM1, and secrete high levels of chemokines, such as IL6 and CC chemokine ligand 2 (CCL2; also known as MCP1) 176 .

TGFβ ligands bind to TGFβR1 (also known as ALK5) and TGFβR2. Type III receptors (TGFβR3) increase ligand binding to their cognate receptors. Although endothelial ALK5 and TGFβR2 are crucial for cere bral vascular development 177 and endothelial TGFβR3 for coronary vessel development 178 in mouse embryos, Alk5 or Tgfbr2 deletion in endothelial cells in adult mice does not affect vascular morphogenesis 179 . Activation of the TGFβ pathway in endothelial cells in adult mice and humans is associated with a change in endothelial cell identity referred to as EndMT, a cell fate change event underlying a number of pathological processes 32 (Figs1,2). When endothelial cells undergo EndMT, they acquire mesenchymal characteristics including fibroblast like morphology, cell junction rearrange ment, increased mobility and proliferation, a throm bogenic and inflamma tory phenotype, and increased secretion of the extracellular matrix proteins fibronec tin and collagen 180 . To date, at least three pathways that inhibit TGFβ signalling in quiescent endothelia have been identified: the VEGF/FGF-ERK-let7 pathway and the BMP9-ALK1 pathway discussed above, and the cerebral cavernous malformation (CCM)-MEKK3 pathway 10, 30, 150, 181 . Postnatal deletion of any of the three known CCM genes in mice leads to overactivation of the MEKK3 pathway 182, 183 , which induces the expres sion of Klf4 (which encodes the transcription fac tor Krüppel like factor 4 (KLF4)) 181 and Klf2 (which encodes KLF2) 184 . The exact mechanism of how KLF2 and KLF4 induce CCM lesion formation is unclear. One study showed that KLF4 induces an autocrine loop that involves BMP6, which activates the TGFβ pathway leading to EndMT 181 . However, another study found that CCM gene deletion induces MEKK3 mediated overac tivation of KLF2 and KLF4, but that this overactivation does not induce EndMT 183 . Interestingly, an ensemble computational intelligence strategy, comprising deep learning and probabilistic programming of RNA seq data, causally linked the loss of ERK1 and ERK2 in human endothelial cells in vitro to the activation of an autocrine loop driven by TGFβ2 (reF. 10 ). Verified in mice, this autocrine loop resulted not only in the induction of EndMT (seen in vitro and in vivo in Erk1 −/− Erk2 iEC−/− mice), but also in systemic hypertension. The latter was induced by suppression of eNOS expression (and there fore NO production) and induction of vasoconstrictor ET1 expression. A decrease in endothelial fenestration was also observed (caused by decreased PV1 expression as seen in vitro and in vivo in Erk1 −/− Erk2 iEC−/− mice) 10 (Fig. 2) . Systemic hypertension and the loss of endothelial fenestrations are features of VEGF-ERK pathway inhi bition. This in silico analysis suggested that the pheno types seen after the loss of VEGF signalling are, at least partially, due to increased TGFβ signalling.

Fibrosis is a devastating process characterized by myofibroblast cell proliferation and abnormal extra cellular matrix accumulation, leading to organ failure. Endothelial cell injury often precedes the development of fibrosis and is suspected to be an initiating event 185 ( Table 2 ). Endothelial cells produce profibrotic medi ators, such as TGFβ, plasminogen activator inhibitor 1 and connective tissue growth factor, which induce fibroblast growth and differentiation and collagen syn thesis by fibroblasts 186 . In addition, endothelial cells can also differentiate into fibroblast like cells and secrete collagen as a result of EndMT 32 . However, the exact contribution of EndMT as the source of myofibroblasts is controversial, and lineage tracing experiments in animal models of cardiac and renal fibrosis show that EndMT is not a major source of myofibroblasts [187] [188] [189] [190] [191] . Liver sinusoidal endothelial cells (LSECs) have a major role in liver fibrosis 192, 193 . After liver injury, LSECs rap idly switch from a fenestrated to a capillarized phenotype and acquire a pro vasoconstrictive, pro inflammatory, pro angiogenic and pro fibrotic phenotype, which induces hepatic stellate cell activation that leads to liver fibrosis. VEGF and BMP9 can both function to maintain the fenestrated quiescent state of LSECs 145, 194 . Inflammatory cells also contribute to the development of fibrosis. Activated endothelial cells provide important signals, such as the expression of adhesion molecules (for example, ICAM1 and VCAM1) and secretion of vari ous cytokines and chemokines (such as IL6, CCL2 and

• What is the genetic and metabolic basis of endothelial heterogeneity? • What determines disease-prone versus disease-resistant endothelial cell subsets? • What are the organ-specific signals governing endothelial cell specialization and final differentiation? • What are the main organ-specific interactions between endothelial cells and non-endothelial cells?

CXC chemokine ligand 12), to recruit leukocytes and perpetuate inflammation. This pro inflammatory pheno type of endothelial cells and the recruitment of inflam matory cells contribute to the pro fibrotic environment by inducing the secretion of collagen 195 . Activation of the TGFβ pathway in endothelial cells triggers an endothelial inflammatory phenotype 39 . In addition, TGFβ secreted by endothelial cells can induce resident fibroblasts to become myofibroblasts 196 . Finally, activation of the TGFβ pathway is also a major trigger of plaque formation in atherosclerosis, as a consequence of decreased FGF signalling (see the section on FGF signalling) 39, 42 .

Endothelial quiescence has emerged as an important area of investigation in the field of vascular biology research. The vascular endothelium is central to the regulation of tissue and organ homeostasis and is cru cial for disease resilience. Understanding the signalling pathways that regulate the numerous functions of the quiescent endothelium in different organs is central to the understanding of normal physiology as well as the pathophysiology of numerous diseases, and addressing important knowledge gaps is the current challenge in the field of vascular biology (box 1). Although many functions of the quiescent endothe lium are organ specific (Fig. 1) , other functions are general to all quiescent endothelial cells. Thus, the TGFβ signal ling pathway is inhibited in the healthy quiescent endothe lium regardless of organ or location, and activation of TGFβ is linked to the loss of normal endothelial cell fate (via EndMT) and to the development and progres sion of disease states (Figs 1,2) . Indeed, the capacity of an endothelial bed to avoid the activation of TGFβ signalling is closely linked to its capacity to resist disease develop ment and might account for different disease susceptibil ities in different patient populations. It is interesting to speculate that an increased susceptibility of endothelial cells to TGFβ activation might be a risk factor for some of the most common vascular diseases, such as atheroscle rosis. The ability to understand and assess this endothelial cell susceptibility, both genetically and functionally, would allow better risk assessment and the development of therapies aimed at disease prevention. The importance of keeping TGFβ signalling in check is further illustrated by the variety of signalling cascades that inhibit TGFβ signalling in endothelial cells, including VEGF-ERK, FGF-ERK, BMP9-ALK1 and CCM-MEKK3 (Fig. 2) . The existence of these signalling cascades suggests that control of TGFβ signalling is crucial for maintaining cell homeostasis and that abnormalities in this pathway can trigger specific diseases.

Endothelial cell senescence and ageing are crucially linked to endothelial cell quiescence, and endothelial normalcy is probably one of the most crucial factors contributing to a healthy lifespan. Examples of such a link include arterial stiffness and hypertension, two hallmarks of the ageing process. Although this subject is outside the scope of this Review, the mechanisms of ageing related endothelial cell senescence have been well described previously 197 .

A thorough knowledge of the dynamic control of endothelial quiescence is required. To this end, we need to understand how a signalling pathway that is involved in angiogenic stimulation, such as VEGF signalling, can also maintain endothelial quiescence. This dichotomy could be a result of different VEGF dosages, differential VEGF signalling through different co receptors, such as neuropilin 1 (reFs 198, 199 ) and syndecan 2 (reF. 200 ), alter ations in the duration of VEGF stimulation, paracrine versus endocrine versus autocrine activation of VEGF signalling, or crosstalk with other signalling pathways. All these factors might differentially affect VEGF stimu lation and point towards the existence of regulators that modulate the effects of VEGF signalling to achieve the desired physiological objective 201, 202 .

We also need to understand the molecular basis of the organotypic effects of endothelial cell signalling. For example, although CCM proteins are expressed in all endothelial cells, variants in CCM genes seem to affect only the central nervous system vasculature. Another related problem is that organ specific mutation of genes in a given signalling pathway does not have a consistent pheno type across organs. Genetic variants in ACVRL1 and ENG lead to the development of HHT (with AVM mainly in the lungs and liver), whereas variants in BMPR2 predispose to the development of pulmonary hypertension, with no effect on the vasculature of other organs.

Advances in research into endothelial cell metab olism show a difference in the metabolic signature between quiescent and activated endothelial cells 203 . Of note, alterations in endothelial cell metabolism could be very important to regulate cell quiescence and warrant further investigation.

Another important unknown is the link between endothelial cell quiescence and disease resilience. Emerging data from single cell RNA seq studies high light the heterogeneity of endothelial cells between tissues but also within each tissue 11 (Fig. 3a,b) . These single cell RNA seq data suggest that in many cases, disease progression is due to the expansion of a single population of normal cells (for example, endothelial or smooth muscle cells) that are susceptible to a particular disease stimulus 42, 204, 205 (Fig. 3c) . These findings also sug gest that other normal populations of these cell types are disease resistant. An in depth understanding of this phenomenon is crucially important. Further studies to characterize the genetic, molecular and metabolic signa tures of disease resistant versus disease prone cell popu lations are also needed (box 1; Fig. 3c ). To summarize, the understanding of the active regulation of the organotypic endothelial quiescence is currently one of the biggest challenges in vascular biology research.

Published online xx xx xxxx Fig. 3 | Endothelial heterogeneity in health and disease. a | Quiescent endothelial cell (EC) heterogeneity in structure, function, immune regulation (interferon response and leukocyte adhesion molecule expression) and metabolism between tissues and within tissues. The information shown in this panel a is from reF. 11 . b | Heterogeneity in healthy capillary ECs between organs. c | Development of endothelial dysfunction. This is a stepwise process, progressing from activation of ECs to the development of endothelialto-mesenchymal transition to the full-blown pathological end state. This sequence of events leads to ECs losing their normal fate and acquiring features of mesenchymal cell types, including fibroblasts, smooth muscle cells and macrophages, in a process known as endothelial-to-mesenchymal transition. These events result in the initiation and propagation of inflammation, loss of normal endothelial structures and function, increased vascular permeability and formation of pathological lesions, such as atherosclerotic plaques.

Endothelial cells: from innocent bystanders to active participants in immune responses

Endothelial cell control of thrombosis

Endothelial dysfunction and hypertension

Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability

The endothelial tip-stalk cell selection and shuffling during angiogenesis

Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice

Endothelial-directed hepatic regeneration after partial hepatectomy

Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis

Role of the VEGF -a signaling pathway in the glomerulus: evidence for crosstalk between components of the 0123456789();: glomerular filtration barrier

Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium

Single-cell transcriptome atlas of murine endothelial cells

Endothelial cell gene regulation

Endothelial cell diversity revealed by global expression profiling

Human organ-specific endothelial cell heterogeneity

Endothelial cell heterogeneity. Cold Spring Harb

Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation

Molecular signatures of tissuespecific microvascular endothelial cell heterogeneity in organ maintenance and regeneration

The endothelial cell

Organotypic vasculature: from descriptive heterogeneity to functional pathophysiology

An analysis of the permeability of a fenestra

Dynamics of cell generation and turnover in the human heart

The fibroblast growth factor signaling pathway

FGF-dependent metabolic control of vascular development

The FGF system has a key role in regulating vascular integrity

FGF-dependent regulation of VEGF receptor 2 expression in mice

Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis

Fibroblast growth factor signaling potentiates VE-cadherin stability at adherens junctions by regulating SHP2

Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo

Basic FGF treatment of endothelial cells down-regulates the 85-kDa TGFβ receptor subtype and decreases the growth inhibitory response to TGF-β1

FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression

FGF-1 reverts epithelial-mesenchymal transition induced by TGF-β1 through MAPK/ERK kinase pathway

The molecular basis of endothelial cell plasticity

FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-β signaling

Fluid shear stress sensing in vascular homeostasis and remodeling: towards the development of innovative pharmacological approaches to treat vascular dysfunction

Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling

Fibroblast growth factor-specific modulation of cellular response by syndecan-4

Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway

Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo

Endothelial-to-mesenchymal transition drives atherosclerosis progression

Atherosclerotic cardiovascular disease beginning in childhood

Shear stress and atherosclerosis

Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis

Mechanisms and regulation of endothelial VEGF receptor signalling

The role of vascular endothelial growth factor-B in metabolic homoeostasis: current evidence

VEGF in signaling and disease: beyond discovery and development

Placental growth factor and pre-eclampsia

Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis

Vascular endothelial growth factor localization in the adult

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease

Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy

Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice

Conditional hypovascularization and hypoxia in islets do not overtly influence adult β-cell mass or function

VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis

Autocrine VEGF signaling is required for vascular homeostasis

Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex

Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase

Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression

Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1

VEGF inhibition and renal thrombotic microangiopathy

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases

Preeclampsia: novel mechanisms and potential therapeutic approaches

Maternal plasma level of endothelin is increased in preeclampsia

Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women

Maternal serum transforming growth factor beta-2 in preeclampsia and eclampsia, a potential biomarker for the assessment of disease severity and fetal outcome

Preeclampsia: updates in pathogenesis, definitions, and guidelines

Inhibition of VEGF receptors causes lung cell apoptosis and emphysema

Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries

The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis

DLL4/Notch1 and BMP9 interdependent signaling induces human endothelial cell quiescence via P27KIP1 and thrombospondin-1

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF

Pulmonary arterial hypertension in patients treated by dasatinib

Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome

The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China

Analysis of 92 deceased patients with COVID-19

New insights into the mechanisms of pulmonary edema in acute lung injury

Advances in understanding of the pathogenesis of acute respiratory distress syndrome

Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome

Vascular endothelial growth factors in pulmonary edema: an update

VEGF upregulation in viral infections and its possible therapeutic implications

Elevated VEGF levels in pulmonary edema fluid and PBMCs from patients with acute hantavirus pulmonary syndrome

Elevated vascular endothelial growth factor levels induce hyperpermeability of endothelial cells in hantavirus infection

Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis

Wnt/β-catenin signaling controls development of the blood-brain barrier

Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity

Interplay of the Norrin and Wnt7a/Wnt7b signaling systems in blood-brain barrier and blood-retina barrier development and maintenance

Canonical WNT signaling components in vascular development and barrier formation

The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence

Netrin 1 regulates blood-brain barrier function and neuroinflammation

Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis

Dysfunctional Wnt/β-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease

Huntington's disease iPSC-derived brain microvascular endothelial cells reveal WNT-mediated angiogenic and blood-brain barrier deficits

Isolation of a candidate gene for Norrie disease by positional cloning

Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a highaffinity ligand-receptor pair

Dysregulation of sonic hedgehog pathway and pericytes in the brain after lentiviral infection

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues

Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway

Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin

Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor

Tie2 protects the vasculature against thrombus formation in systemic inflammation

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands

Tie1 controls angiopoietin function in vascular remodeling and inflammation

VEGF receptor signal transduction -a brief update

Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner

Stability and function of adult vasculature is sustained by Akt/Jagged1 signalling axis in endothelium

The endothelial transcription factor ERG mediates angiopoietin-1-dependent control of Notch signalling and vascular stability

The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling

Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2

Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects

Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities

Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB

VE-PTP controls blood vessel development by balancing Tie-2 activity

Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP

The interactivity between TGFβ and BMP signaling in organogenesis, fibrosis, and cancer

A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma

Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells

Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis

Arteriovenous malformations in mice lacking activin receptor-like kinase-1

ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway

BMP9 and BMP10 are critical for postnatal retinal vascular remodeling

Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia

Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models-brief report

Loss of endothelial endoglin promotes high-output heart failure through peripheral arteriovenous shunting driven by VEGF signaling

VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2

Bone morphogenetic protein-9 is a circulating vascular quiescence factor

PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia

Bone morphogenetic protein 9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting against hepatic fibrosis

Differential consequences of Bmp9 deletion on sinusoidal endothelial cell differentiation and liver fibrosis in 129/Ola and C57BL/6 mice

Defective fluid shear stress mechanotransduction mediates hereditary hemorrhagic telangiectasia

Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues

Primary cilia sensitize endothelial cells to BMP and prevent excessive vascular regression

Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension

The transcriptomic and epigenetic map of vascular quiescence in the continuous lung endothelium

Dynamic regulation of canonical TGFβ signalling by endothelial transcription factor ERG protects from liver fibrogenesis

Hereditary hemorrhagic telangiectasia: from molecular biology to patient care

Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment

Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

Mutations in the activin receptorlike kinase 1 gene in hereditary haemorrhagic telangiectasia type 2

Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations

Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function

Somatic mutations in vascular malformations of hereditary hemorrhagic telangiectasia result in Bi-allelic loss of ENG or ACVRL1

Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network

Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers

Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia

Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population

Liver involvement in hereditary hemorrhagic telangiectasia (HHT)

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output

Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension

BMPR2 inhibits activin and BMP signaling via wild-type ALK2

Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension

Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases

Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension

Physiologic and molecular consequences of endothelial Bmpr2 mutation

Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/ CD74 complex

TGF-β signaling in endothelial cells, but not neuroepithelial cells, is essential for cerebral vascular development

Coronary vessel development is dependent on the type III transforming growth factor beta receptor

ALK5-and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2

The basics of epithelialmesenchymal transition

KLF4 is a key determinant in the development and progression of cerebral cavernous malformations

The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression

Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling

Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins

Endothelium-mediated contributions to fibrosis

Pulmonary microvascular endothelial cells from bleomycin-induced rats promote the transformation and collagen synthesis of fibroblasts

Origin and function of myofibroblasts in kidney fibrosis

Cellular and molecular mechanisms of kidney fibrosis

Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation

Genetic lineage tracing defines myofibroblast origin and function in the injured heart

Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities

The endothelium as a driver of liver fibrosis and regeneration

Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease

Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence

Bleomycin increases neutrophil adhesion to human vascular endothelial cells independently of upregulation of ICAM-1 and E-selectin

Stimulation of rat endothelial cell transforming growth factor-beta production by bleomycin

Endothelial cell senescence in aging-related vascular dysfunction

PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells

Neuropilin regulation of angiogenesis

N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA165-dependent neovascularization

Computational approaches for analyzing information flow in biological networks

The dynamic control of signal transduction networks in cancer cells

Hallmarks of endothelial cell metabolism in health and disease

Smooth muscle cell reprogramming in aortic aneurysms

Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells

M.S. is supported, in part, by NIH grants HL135582, HL149343 and HL107205.

All the authors researched data for the article, provided substantial contributions to discussions of its content, wrote the article, and reviewed and/or edited the manuscript before submission.

The authors declare no competing interests.

Nature Reviews Cardiology thanks the anonymous reviewers for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.